Improving Stroke Prevention in Patients With Atrial Fibrillation.

Slides:

Advertisements

Similar presentations

ATRIAL FIBRILLATION.

Advertisements

Apixaban versus Aspirin in Atrial Fibrillation Patients ≥ 75 years old: An Analysis from the AVERROES Trial Kuan H Ng, Olga O Shestakovska, John W. Eikelboom,

A Patient’s Voice John’s* perspective is shared in each section. John is a 75-year-old retired surgeon with atrial fibrillation who has been taking warfarin.

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,

Cerebrovascular prevention in cardiac failure George Ntaios University of Thessaly, Larissa, Greece Lausanne 6/09/2012.

Stroke prevention in atrial fibrillation

Atrial Fibrillation Stroke Prevention with Oral Anticoagulants Why is there discordance between guideline committees & specialists when the data is based.

Anticoagulation? Antiplatelet? What’s the Score? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.

AF and NOACs An UPDATE JULY 2014

Rohan Subasinghe.  Non valvular aF increases with age from 0.5 % at age to 9 % at age  AF is an independent Risk factor for CVA  Patients.

ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.

CHADS 2 -> CHA 2 DS 2 VASc. CHA2DS2-VASc Risk Score CHF or LVEF < 40% 1 Hypertension1 Age > 752 Diabetes1 Stroke/TIA/ Thromboembolism 2 Vascular Disease.

CHADS, SHMADS: What’s All This About Anticoagulation? COPYRIGHT © 2016, ALL RIGHTS RESERVED From the Publishers of.

WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.

CVD MEETING 7/9/01: main topics CV CLINIC WITH SCREEN SHOTS AND AUDIT MANAGEMENT PROTOCOL WITH DRUGS AND RISK CALCULATION CHARTS ASPIRIN AUDIT.

Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,

Warfarin PSD/HOF001/GB/DC/Rev013 Issued : Review interval:12 months This document may be reviewed and reissued electronically without notice.

Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.

Stoke On Trent CCG – Atrial Fibrillation Service AF Nurse in GP Practice Interfacing Primary and Secondary Care for AF Stroke Prevention Jodie Williams.

Prevention of thromboembolism in AF ACC/AHA/ESC Guidelines Jin-Bae Kim, MD, PhD Arrhythmia Service, Division of Cardiology Cardiovascular Center, Kyung.

ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.

The Management of AF Warfarin New anticoagulants 16 Sept 2011.

R2. 최태웅 / Pf. 김진배. BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic.

Date of download: 7/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Choice of Antithrombotic Therapy for Stroke Prevention.

1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.

Cara Coffelt, PharmD PGY-1 Pharmacy Resident

LAA Closure: Lessons from the Pivotal Studies & Three Advisory Panels

Exploring Factors Associated with Preferential Prescribing of Apixaban Over Warfarin in Patients with Non-Valvular Atrial Fibrillation Scott McColgana,

How Do We Incorporate Patient Perspectives Into Clinical Trial Design?

An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.

Addressing the Challenges in Primary and Secondary Stroke Prevention

David R. Holmes, Jr., M.D. Mayo Clinic, Rochester

Anticoagulation in Atrial Fibrillation

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

Atrial Fibrillation and PCI

NOACs In Long-term VTE Treatment: A State Of The Art Review

NOACs, AF, and PCI: What Do the Latest Data Suggest?

ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Access to NOAC Therapy:

Nat. Rev. Cardiol. doi: /nrcardio

Educational Event 23rd & 24th January 2013

Up to Date on Which NOAC for Which Patient

Fibrillazione atriale

Oral Anticoagulants in AFa,b A Brief History.

Selecting NOACs for High-Risk Patients

Antiplatelet Therapy and Secondary Prevention

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Access to NOAC Therapy:

Adherence in SPAF: Measures to Improve Care

What Anticoagulant Registries Are Revealing

Watching for the Patient With AF: Latest Advances and Technologies

Atrial Fibrillation.

NOACs in AF: Consequences of Underdosing and NonAdherence

Identifying High-Risk AF Patients

Factor Xa Inhibitors in PAD

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Which NOAC and When for Stroke Prevention in AF?

NOACs in AF: Consequences of Underdosing and NonAdherence

5 Good Minutes on Atrial Fibrillation-related Stroke

Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation David R. Holmes, MD, Mohamad Alkhouli,

Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.

The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.

Presentation transcript:

Improving Stroke Prevention in Patients With Atrial Fibrillation

Acknowledgement

Disclosures

Disclosures (cont.) This presentation will not include any non-FDA approved or investigational uses of products or medical devices.

Learning Objectives

Atrial Fibrillation (AF): Incidence and Consequences

Projected Number of Persons With AF in the US: 2000 to 2050

AF and Stroke

Greater Risk of Death and Recurrence With AF Strokes

Disability vs Age Group in Those With Acute Ischemic Stroke (AIS) vs AF-AIS

Anticoagulation: Assessing Benefits and Risks

Question

Case 1

CHADS 2 Index: A Validated Classification Scheme/Tool for Stroke Risk

Weakness of CHADS 2

The CHA 2 DS 2 -VASc Index

CHA 2 DS 2 -VASc vs CHADS 2 : Which to Use?

Case 2

ACC/AHA/ESC Guidelines

Risk Stratification and Anticoagulation

Underuse of Anticoagulants in AF

Barriers to Anticoagulant Use

Barriers to Anticoagulation?

Bleeding Risk

Bleeding Risk: The Reality

Anticoagulation in Patients at Risk of Falls: “Physicians’ Fears Are Often Unfounded”

Assessing Bleeding Risk: HAS-BLED

Reducing Bleeding Risk

Anticoagulation Decision Support Worksheet

Anticoagulation Decision Support Worksheet (cont.)

The Patient: Decision Making and Education

Patient Preferences

Patient vs Physician Perspectives on Anticoagulation

Explaining Risk to Patients: Numerous Tools Available

Patient Knowledge About Warfarin

Patient Adherence to Warfarin

Risk Factors for Warfarin Nonadherence

Improving Patient Adherence to Anticoagulants

Which Antithrombotic Therapy?

Generic/Trade Name Guide for Drugs Mentioned in Presentation

Features of Available Anticoagulants

Warfarin and Novel Anticoagulant Mechanisms of Action

Choosing an Anticoagulant

Question Check

Clopidogrel and/or Aspirin?

ACC/AHA/ESC Guidelines: Warfarin vs Aspirin

Warfarin: The Gold Standard

Currently Available Oral Anticoagulants

Clinical Trial Data

Limitations/Concerns With Available Anticoagulants

Visit TEAManticoag.com for a Medication Chart (Keyword: chart)

ACC/AHA/ESC Guidelines: Managing Through Medical Procedures to Prevent Thrombosis

Drug-Specific Guidelines for Managing Through Medical Procedures

When to Switch From Warfarin

Remain With Warfarin if …

Switching From Warfarin: How?

Visit TEAManticoag.com for Tools, Handouts, Calculators, and More

Periprocedural Anticoagulation Algorithm on TEAManticoag.com (Keyword: periprocedural)

Decision Tool to Use With Patients on TEAManticoag.com (Keyword: decision)

TEAM-A Town Hall on TEAManticoag.com